Felix Darstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Felix Darstein has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Peter Robert Galle
Department of Internal Medicine I University Medical Center of the Johannes Gutenberg‐University Mainz Germany
4 shared publications - Hauke Lang
Department of General, Visceral and Transplant Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
3 shared publications - Jens Mittler
Department of General, Visceral and Transplant Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
3 shared publications - Maria Hoppe-Lotichius
Klinik fur Allgemein-, Viszeral- und Transplantionschirurgie, Universitatsmedizin Mainz, Mainz, Germany
3 shared publications - Tim Zimmermann
Osnabrück University, Osnabrück, Germany
3 shared publications A. Zimmermann
First Department of Internal Medicine, Gastroenterology and Hepatology, Universitätsmedizin Mainz, Mainz, Germany
2 shared publications
Latest Publications
- 1 April 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (3) , 926-931
Hepatitis E Is a Rare Finding in Liver Transplant Patients With Chronic Elevated Liver Enzymes and Biopsy-Proven Acute Rejection
- 1 April 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (3) , 926-931
Hepatitis E Is a Rare Finding in Liver Transplant Patients With Chronic Elevated Liver Enzymes and Biopsy-Proven Acute Rejection
- 19 September 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (11) , e13411
Hepatitis E virus genotype 3 is a common finding in liver‐transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real‐world cohort
Background: Hepatitis E virus (HEV) infection is a potential reason for elevated liver enzymes after liver transplantation (LT). Our aim was to analyze a real‐world cohort of LT patients, who underwent liver biopsy for elevated transaminases and suspected acute rejection, to evaluate frequency of post‐transplant HEV infection.Patients: Data from 160 liver biopsies were analyzed. Seventy‐one patients were biopsied on schedule after LT without elevated liver enzymes. A subgroup of 25 patients with elevated liver enzymes and suspected rejection was chosen for further analysis. Patient demographics and data were retrieved from a clinical database, patients’ charts, and reports.Results: Hepatitis E virus infection was diagnosed in five of 25 patients with suspected acute rejection (20%). HEV genotype 3 was detected in three of the five HEV‐infected patients. Patients with HEV infection showed higher ALT levels (P = 0.014), lower De Ritis ratio (P = 0.021), and more frequent glucocorticoid therapy (P = 0.012) compared to HEV‐negative patients.Conclusion: We found a rate of 20% HEV infections in LT patients undergoing liver biopsy for elevated liver enzymes and suspected acute rejection. These data indicate the necessity for HEV testing in all LT patients with elevated liver enzymes and suspected acute rejection.
- 19 September 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (11) , e13411
Hepatitis E virus genotype 3 is a common finding in liver‐transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real‐world cohort
Background: Hepatitis E virus (HEV) infection is a potential reason for elevated liver enzymes after liver transplantation (LT). Our aim was to analyze a real‐world cohort of LT patients, who underwent liver biopsy for elevated transaminases and suspected acute rejection, to evaluate frequency of post‐transplant HEV infection.Patients: Data from 160 liver biopsies were analyzed. Seventy‐one patients were biopsied on schedule after LT without elevated liver enzymes. A subgroup of 25 patients with elevated liver enzymes and suspected rejection was chosen for further analysis. Patient demographics and data were retrieved from a clinical database, patients’ charts, and reports.Results: Hepatitis E virus infection was diagnosed in five of 25 patients with suspected acute rejection (20%). HEV genotype 3 was detected in three of the five HEV‐infected patients. Patients with HEV infection showed higher ALT levels (P = 0.014), lower De Ritis ratio (P = 0.021), and more frequent glucocorticoid therapy (P = 0.012) compared to HEV‐negative patients.Conclusion: We found a rate of 20% HEV infections in LT patients undergoing liver biopsy for elevated liver enzymes and suspected acute rejection. These data indicate the necessity for HEV testing in all LT patients with elevated liver enzymes and suspected acute rejection.
- Open Access
- 12 February 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment
The polyspecific organ cation transporter 1 (OCT1) is one of the most important active influx pumps for drugs like the kinase inhibitor sorafenib. The aim of this retrospective study was the definition of the role of intratumoral OCT1 mRNA expression in hepatocellular carcinoma (HCC) as a biomarker in systemic treatment with sorafenib. OCT1 mRNA expression levels were determined in biopsies from 60 primary human HCC by real time PCR. The data was retrospectively correlated with clinical parameters. Intratumoral OCT1 mRNA expression is a significant positive prognostic factor for patients treated with sorafenib according to Cox regression analysis (HR 0.653, 95 %-CI 0.430-0.992; p = 0.046). Under treatment with sorafenib, a survival benefit could be shown using the lower quartile of intratumoral OCT1 expression as a cut-off. Macrovascular invasion (MVI) was slightly more frequent in patients with low OCT1 mRNA expression (p = 0.037). Treatment-induced AFP response was not associated with intratumoral OCT1 mRNA expression levels (p = 0.633). This study indicates a promising role for intratumoral OCT1 mRNA expression as a prognostic biomarker in therapeutic algorithms in HCC. Further prospective studies are warranted on this topic.
- 12 February 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Open AccessOrganic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment
The polyspecific organ cation transporter 1 (OCT1) is one of the most important active influx pumps for drugs like the kinase inhibitor sorafenib. The aim of this retrospective study was the definition of the role of intratumoral OCT1 mRNA expression in hepatocellular carcinoma (HCC) as a biomarker in systemic treatment with sorafenib. OCT1 mRNA expression levels were determined in biopsies from 60 primary human HCC by real time PCR. The data was retrospectively correlated with clinical parameters. Intratumoral OCT1 mRNA expression is a significant positive prognostic factor for patients treated with sorafenib according to Cox regression analysis (HR 0.653, 95 %-CI 0.430-0.992; p = 0.046). Under treatment with sorafenib, a survival benefit could be shown using the lower quartile of intratumoral OCT1 expression as a cut-off. Macrovascular invasion (MVI) was slightly more frequent in patients with low OCT1 mRNA expression (p = 0.037). Treatment-induced AFP response was not associated with intratumoral OCT1 mRNA expression levels (p = 0.633). This study indicates a promising role for intratumoral OCT1 mRNA expression as a prognostic biomarker in therapeutic algorithms in HCC. Further prospective studies are warranted on this topic.
- 6 June 2015
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 26 (6) , 439-444
New onset of diabetes after transplantation is associated with improved patient survival after liver transplantation due to confounding factor
- 6 June 2015
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 26 (6) , 439-444
New onset of diabetes after transplantation is associated with improved patient survival after liver transplantation due to confounding factor
- 1 March 2014
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 25 (3) , 281-285
Impact of pancreatic comorbidities in patients with end-stage liver disease on outcome after liver transplantation
- 1 March 2014
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 25 (3) , 281-285
Impact of pancreatic comorbidities in patients with end-stage liver disease on outcome after liver transplantation